Bejelentkezés Regisztrálj ingyen

Neovacs S.A Beta

Mi az Neovacs S.A Beta?

A Beta az Neovacs S.A. - 0.82

Mi a Beta meghatározása?



A BETA azt jelzi, hogy az állomány több-kevésbé volatilis, mint a piac egésze. Az 1-nél kevesebb béta azt jelzi, hogy az állomány kevésbé ingadozó, mint a piac, míg az 1-nél nagyobb béta azt jelzi, hogy az állomány volatilisabb. A volatilitást az átlag körüli ár ingadozásaként méri.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta a Health Care szektor a EURONEXT-on cégekben a Neovacs S.A -hoz képest

Mit csinál Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

beta -hoz hasonló cégek Neovacs S.A